Yonhap Infomax NewsNov 28
Celltrion has obtained Health Canada approval for its Eylea biosimilar Eydenzelt, targeting the $9.5 billion global ophthalmology market with both vial and prefilled syringe formulations.
#YonhapInfomax #Celltrion #Eydenzelt #HealthCanada #Eylea #BiosimilarApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=93039
Celltrion Secures Approval for Eylea Biosimilar 'Eydenzelt' in Canada

Celltrion has obtained Health Canada approval for its Eylea biosimilar Eydenzelt, targeting the $9.5 billion global ophthalmology market with both vial and prefilled syringe formulations.

Yonhap Infomax